Disclaimer: Information regarding Retatrutide is based on ongoing clinical trials and is subject to change upon final FDA approval
Who Should Be Cautious or Avoid It Growth hormone peptides are generally not appropriate during pregnancy, for people with active or recent cancer (because growth signaling and cell growth are linked), or where there are certain pituitary or metabolic conditions
If you can use less hot water in your shower, that's better
Biosimilar development is the medium-term democratization opportunity Biocon Biologics, Samsung Bioepis, and other biosimilar developers are advancing semaglutide biosimilar programs that, upon patent expiry, could reduce drug costs by 70-85% and dramatically expand patient access in both developed markets with coverage barriers and developing markets with affordability constraints
maximum doses vary by indication
Thus, peptide might be considered as an effective anti-inflammatory and anti-fungal treatment in the future